8-K: INmune Bio to Host Webinar on EMACC Cognitive Testing for Early Alzheimer's Trials

INmune Bio will host a webinar on November 7, 2024, to discuss the use of EMACC for measuring cognitive change in early Alzheimer's trials, following a poster presentation at the CTAD conference.

Summary

• INmune Bio is hosting a webinar on November 7, 2024, to discuss the Early and Mild Alzheimer's Cognitive Composite (EMACC) tool.
• The webinar will focus on why EMACC is considered an optimal tool for measuring cognitive changes in early Alzheimer's disease (AD) trials.
• The company is presenting a poster at the Clinical Trial in Alzheimer's Disease (CTAD) conference on the EMACC's sensitivity and performance in a Phase II Alzheimer's trial.
• The EMACC is a validated cognitive measure composed of standardized neuropsychological tests.
• It is designed to accurately capture cognitive changes in early AD, unlike other measures such as CDR-SB and ADAS-Cog.
• The company believes that the EMACC has the potential to improve AD clinical development by enabling smaller and shorter clinical trials.
• INmune Bio is currently conducting a Phase II trial using XPro in early AD patients, with the primary endpoint being cognitive function change measured by EMACC and CDR-SB after 6 months.
• The trial focuses on patients with neuroinflammation as a cause of their cognitive decline.

Sentiment

Score: 7

Explanation: The document is positive about the potential of the EMACC tool and the company's research efforts, but it also acknowledges the risks associated with clinical trials and the need for further funding.

Positives

• The EMACC is presented as a superior tool for measuring cognitive change in early AD trials compared to other methods.
• The use of EMACC could lead to smaller, shorter, and less expensive clinical trials.
• The company is actively researching and developing treatments for Alzheimer's disease.
• The company is presenting data at a major medical conference, CTAD, indicating a commitment to sharing research findings.

Negatives

• The company's products are still in clinical trials and have not been approved by the FDA or any regulatory body.
• There is no assurance that any specific outcome will be achieved in the clinical trials.

Risks

• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding for the company to continue operations and conduct research and development is a risk.
• The company's business, research, product development, regulatory approval, marketing and distribution plans and strategies are subject to risks and uncertainties.
• Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.

Future Outlook

The company is focused on advancing its clinical trials and believes that the EMACC has the potential to improve AD clinical development. However, there is no assurance that any specific outcome will be achieved.

Management Comments

• Dr. Jaeger stated that clinical trials measure change in cognition, not disease stage.
• CJ Barnum stated that the EMACC has incredible potential to improve AD clinical development.
• CJ Barnum stated that improving assessment of cognitive change will lead to smaller, shorter clinical trials.

Industry Context

This announcement is relevant to the broader pharmaceutical industry's efforts to develop effective treatments for Alzheimer's disease. The focus on a more precise cognitive measurement tool like EMACC reflects a trend towards improving clinical trial efficiency and accuracy.

Comparison to Industry Standards

• The document mentions that EMACC was used in the Biogen Tango Study of the gosenuremab program (BIIB092), indicating a comparison to a major pharmaceutical company's clinical trial.
• The document states that EMACC is more accurate than CDR-SB and ADAS-Cog, which are commonly used cognitive assessment tools in Alzheimer's trials.
• The EMACC was also found to be strongly associated with biological markers of inflammation in the Alzheimers Disease Neuroimaging Initiative (ADNI) AD study, which is a well-known and respected study in the field.

Stakeholder Impact

• Shareholders may be interested in the potential of the EMACC tool to improve clinical trial efficiency and reduce costs.
• Patients with Alzheimer's disease may benefit from the development of more effective treatments.
• The company's employees are involved in the research and development of these treatments.

Next Steps

• INmune Bio will host a webinar on November 7, 2024, to discuss the EMACC tool.
• The company will continue its Phase II trial using XPro in early AD patients.
• The company will present a poster at the CTAD conference on the EMACC's sensitivity and performance.

Key Dates

Keywords

EMACC, Alzheimer's Disease, Cognitive Testing, Clinical Trials, Neuroinflammation, XPro, INmune Bio, CTAD, CDR-SB, Biotechnology